Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1050

Sort by

Sort Order Select

Journal Articles

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia-Manero, Elizabeth A. Griffiths, David P. Steensma, Gail J. Roboz, Richard Wells, James McCloskey, II, Olatoyosi Odenike, Amy E. DeZern, Karen Yee, Lambert Busque, Casey O’Connell, Laura C. Michaelis, Joseph Brandwein, Hagop Kantarjian, Aram Oganesian, Mohammad Azab, Michael R. Savona

Blood (2020) 136 (6): 674–683.

https://doi.org/10.1182/blood.2019004143

Published: 2020

Journal Articles

Epigenetic reprogramming sensitizes immunologically silent EBV + lymphomas to virus-directed immunotherapy

Tanner Dalton, Ekaterina Doubrovina, Dmitry Pankov, Raymond Reynolds, Hanna Scholze, Annamalai Selvakumar, Teresa Vizconde, Bhumesh Savalia, Vadim Dyomin, Christoph Weigel, Christopher C. Oakes, Alicia Alonso, Olivier Elemento, Heng Pan, Jude M. Phillip, Richard J. O’Reilly, Benjamin E. Gewurz, Ethel Cesarman, Lisa Giulino-Roth

Blood (2020) 135 (21): 1870–1881.

https://doi.org/10.1182/blood.2019004126

Published: 2020

Includes: Supplemental data

Journal Articles

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

Carsten Riether, PhD, Tanja Chiorazzo, PhD, Amy J. Johnson, PhD, Christina Diane Drenberg, PhD, Khaja Waheeduddin Syed, BPharm, MS, Mahan Moshir, MSc, Anna Hultberg, PhD, Nicolas Leupin, Hans De Haard, Adrian F Ochsenbein, MD

Blood (2019) 134 (Supplement_1): 3918.

https://doi.org/10.1182/blood-2019-127464

Published: 2019

Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 3926.

https://doi.org/10.1182/blood-2019-131930

Published: 2019

Journal Articles

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

Fiona C Brown, Jelena Urosevic, Urszula Polanska, Jan Cosaert, MD PhD, J. Elizabeth Pease, PhD, Giovanna Pomilio, Veronique Litalien, Jon Travers, PhD, Andrew H. Wei

Blood (2019) 134 (Supplement_1): 3930.

https://doi.org/10.1182/blood-2019-129564

Published: 2019

Journal Articles

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Noam E. Kopmar, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Roland B. Walter, MDPhDMS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 2214.

https://doi.org/10.1182/blood-2019-123315

Published: 2019

Journal Articles

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Kazuharu Kamachi, MD, Hiroshi Ureshino, MD, Nao Yoshida, MD, Yuki Kurahashi, Tatsuro Watanabe, PhD, Seiji Okada, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 5365.

https://doi.org/10.1182/blood-2019-125460

Published: 2019

Journal Articles

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Changju Qu, PhD, Nana Ping, MD, PhD, Danqing Kong, MD, Fan Xia, MD, Depei Wu, MD PhD, Zhengming Jin, MD

Blood (2019) 134 (Supplement_1): 5338.

https://doi.org/10.1182/blood-2019-128111

Published: 2019

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

https://doi.org/10.1182/blood-2019-128424

Published: 2019

Journal Articles

A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma

Swetha Kambhampati, MD, Derek Galligan, MD, Guy Ledergor, MD, Thomas G. Martin, III, MD, Jeffrey Wolf, Sandy W. Wong, Nina D. Shah, MD

Blood (2019) 134 (Supplement_1): 5576.

https://doi.org/10.1182/blood-2019-122383

Published: 2019

Journal Articles

Decitabine Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft Versus Host Disease

Yuan Li, MD, Qing Ya Wang, MD, Ze Yin Liang, Yue Yin, Wei Liu, MD PhD, Qian Wang, Yujun Dong, MD, YuHua Sun, Wei Lin Xu, Hanyun Ren, MD PhD

Blood (2019) 134 (Supplement_1): 5647.

https://doi.org/10.1182/blood-2019-125275

Published: 2019

Journal Articles

Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents

Blood (2019) 134 (Supplement_1): 4245.

https://doi.org/10.1182/blood-2019-128949

Published: 2019

Journal Articles

Decitabine-Induced Early Platelet Response, a Predictor of Favorable Outcome during Hypomethylating Treatment of MDS, Is Associated with In Vivo Megakaryocytic Differentiation

Julia Stomper, Annette M. May, Tina E. Joeckel, Peter Bronsert, Martin Werner, Michael Lübbert

Blood (2019) 134 (Supplement_1): 4265.

https://doi.org/10.1182/blood-2019-128141

Published: 2019

Journal Articles

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Blood (2019) 134 (Supplement_1): 4235.

https://doi.org/10.1182/blood-2019-129614

Published: 2019

Journal Articles

Improvement of Survival in JMML By Induction Regimen of Decitabine + Cytarabine + Fludarabine before Hematopoietic Stem Cell Transplantation: Study of 33 Cases in Single Center

Xiaoqin Feng, Zhiyong Peng, MD, Yuelin He, MD, Chunfu Li, MD, Yongsheng Ruan, MD, Xuan Liu, Rongfang Ding, MD, Wanxia Tan

Blood (2019) 134 (Supplement_1): 4267.

https://doi.org/10.1182/blood-2019-130488

Published: 2019

Journal Articles

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome

Kelly S. Chien, MD, Mahesh Swaminathan, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Nicholas J. Short, MD, Kelly Soltysiak, PhD, Sherry A. Pierce, BSN, BA, Jane Waukau, BSN, RN, Darla Miller, Jorge E. Cortes, MD, Yesid Alvarado, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4252.

https://doi.org/10.1182/blood-2019-129226

Published: 2019

Journal Articles

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Guillermo Garcia-Manero, MD, Shyamala C. Navada, MD, Pierre Fenaux, MD PhD, Patrick S. Zbyszewski, MBA, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4268.

https://doi.org/10.1182/blood-2019-132149

Published: 2019

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

Amer M Zeidan, MD, Yasushi Miyazaki, MD PhD, Uwe Platzbecker, Kamel Malek, Julie Niolat, Flavia Kiertsman, Pierre Fenaux, MD PhD

Blood (2019) 134 (Supplement_1): 4259.

https://doi.org/10.1182/blood-2019-127041

Published: 2019

Journal Articles

Molecular Characteristics That Predict Response to Azacitidine Therapy

Blood (2019) 134 (Supplement_1): 4246.

https://doi.org/10.1182/blood-2019-129420

Published: 2019

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Tamara K Moyo, MD PhD, Justin M. Watts, MD, Barry S. Skikne, MD, Jason H. Mendler, MD PhD, Virginia M. Klimek, MD, Sheau-Chiann Chen, PhD, Run Fan, PhD MS, Ingrid A Anderson, PhD, Andrew Sochacki, MD, Stephen A. Strickland, MD, Michael T Byrne, DO, Terrence J Bradley, MD, Gregory D Ayers, MS, Sanjay R Mohan, MD MSCI, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 4236.

https://doi.org/10.1182/blood-2019-130003

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Epigenetic reprogramming sensitizes immunologically silent EBV + lymphomas to virus-directed immunotherapy

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma

Decitabine Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft Versus Host Disease

Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents

Decitabine-Induced Early Platelet Response, a Predictor of Favorable Outcome during Hypomethylating Treatment of MDS, Is Associated with In Vivo Megakaryocytic Differentiation

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Improvement of Survival in JMML By Induction Regimen of Decitabine + Cytarabine + Fludarabine before Hematopoietic Stem Cell Transplantation: Study of 33 Cases in Single Center

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

Molecular Characteristics That Predict Response to Azacitidine Therapy

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only